Results 181 to 190 of about 66,203 (260)

Upstream Stimulatory Factors Regulate HIV-1 Latency and Are Required for Robust T Cell Activation. [PDF]

Viruses, 2023
Horvath RM, Sadowski I.
europepmc   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1514-1521, June 2026.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Ethnopharmacological exploration and isolation of HIV-1 latency-reversing agents from Sudanese medicinal plants. [PDF]

Front Pharmacol
Elamin KM, Kishimoto N, Kawahara T, Idris Elbashir SM, Yasutake T, Wada M, Hitora Y, Kordofani M, Osman W, Elbashir MI, Misumi S.   +10 more
europepmc   +1 more source

New insights into transcription elongation control of HIV-1 latency and rebound. [PDF]

Trends Immunol, 2023
Mbonye U, Kizito F, Karn J.
europepmc   +1 more source

Access to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis‐endemic setting

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract In HIV‐ and tuberculosis (TB)‐endemic regions, lymphoma diagnosis is often delayed because symptoms can overlap with TB, and access to biopsy and specialized pathology is limited. To address this, we developed and internally evaluated the Access to Diagnosis using Liquid Biopsy (ADLiB) platform—a plasma cell‐free DNA (cfDNA)‐based approach ...
Katherine Antel, Nina Xiong, Mwanasha Merrill, Taiyang Chen, Lauren McGrath, Clara Droessler, Maxine van der Schyff, Meng‐Xuan Wu, Dylan Cheddie, Charlotte Slome, Liam McBride, Jonathan Day, Zainab Mohamed, Nazia Fakie, Nomonde Mbatani, Charlotte Shultz, Graeme Meintjes, Svitlana Tyekucheva, Elizabeth F. Cohen, Michael Y. Tolstorukov, Estelle Verburgh, Mark A. Murakami   +21 more
wiley   +1 more source

Impact of chromatin on HIV-1 latency: a multi-dimensional perspective. [PDF]

Epigenetics Chromatin
Jones JE, Gunderson CE, Wigdahl B, Nonnemacher MR.   +3 more
europepmc   +1 more source

Epigenetic silencing by the SMC5/6 complex mediates HIV-1 latency. [PDF]

Nat Microbiol, 2022
Irwan ID, Bogerd HP, Cullen BR.
europepmc   +1 more source

A targeted CRISPR screen identifies ETS1 as a regulator of HIV-1 latency. [PDF]

PLoS Pathog
Ashokkumar M, Hafer TL, Felton A, Archin NM, Margolis DM, Emerman M, Browne EP.   +6 more
europepmc   +1 more source

The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy. [PDF]

Sci Adv, 2023
Prins HAB, Crespo R, Lungu C, Rao S, Li L, Overmars RJ, Papageorgiou G, Mueller YM, Stoszko M, Hossain T, Kan TW, Rijnders BJA, Bax HI, van Gorp ECM, Nouwen JL, de Vries-Sluijs TEMS, Schurink CAM, de Mendonça Melo M, van Nood E, Colbers A, Burger D, Palstra RJ, van Kampen JJA, van de Vijver DAMC, Mesplède T, Katsikis PD, Gruters RA, Koch BCP, Verbon A, Mahmoudi T, Rokx C.   +30 more
europepmc   +1 more source

Efficacy and Safety of Messenger RNA Vaccines

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims The rapid development of mRNA vaccines has revolutionized infectious disease prevention and cancer immunotherapy. While their efficacy is well established, concerns about safety and immunopathological risks persist. This study aims to evaluate the immunogenicity, safety profiles, and design considerations of mRNA vaccines ...
Kesaobaka Batisani, David Chisompola
wiley   +1 more source